However, in the mouse model of IBD, knocking-down PTX3 in CD317+ MSCs reduced the serum level of TSG6 and therapeutic effects (Fig. 7C), while overexpressing PTX3 in CD317− MSCs increased the serum level of TSG6 and therapeutic effects (Fig. 7D), indicating that the PTX3 might regulate the protein stability of TSG6. Here, TNFAIP6 is linked to inflammatory bowel disease.